Eli Lilly (LLY), the world’s highest-valued pharmaceutical company by market capitalization, holds a leading position in the rapidly growing weight management drug market with a massive team of over 49,000 employees. However, this industry giant is facing an unexpected challenger—Viking Therapeutics (VKTX), which has only 48 full-time employees. This mid-sized biotech company is developing innovative therapies that could alter the competitive landscape of the market, presenting new opportunities worthy of investors’ attention.
Eli Lilly’s flagship product, tirzepatide, is the first GLP-1/GIP dual agonist approved by the U.S. Food and Drug Administration. By acting on two different hormones, it demonstrates superior efficacy compared to other GLP-1 drugs. Moreover, Eli Lilly is actively advancing the development of the triple agonist Retatrutide. This investigational drug mimics the actions of three hormones—GLP-1, GIP, and glucagon—and has shown significant potential in clinical trials.
Meanwhile, Viking Therapeutics’ lead candidate, VK2735, also employs a dual-mechanism targeting both GLP-1 and GIP, and is being developed in both subcutaneous and oral formulations. More notably, the company is also developing a dual-therapy targeting amylin and calcitonin. Amylin is involved in regulating blood sugar and satiety, while calcitonin aids in calcium metabolism regulation. Although this therapy is still in the preclinical stage, the company plans to submit an Investigational New Drug (IND) application by the end of the year. Viking’s long-term strategy is to combine VK2735 with the amylin/calcitonin dual-therapy to create a quadruple agonist that mimics the actions of four hormones, potentially pioneering a completely new approach to weight management treatment.
Viking Therapeutics’ R&D pipeline shows encouraging progress. Its subcutaneous formulation of VK2735 performed excellently in Phase II studies and has advanced to Phase III clinical trials. Although the interim data for the oral version present tolerability challenges, the highest dose group achieved a 12.2% weight reduction over 13 weeks, demonstrating considerable potential. By optimizing dosing strategies, such as implementing a gradual dose-escalation regimen, the issue of adverse reactions could potentially be improved. Even if a lower final dose is used, its commercial value could still be proven in full, long-term clinical trials.
Beyond the weight management management, the company’s candidate for metabolic dysfunction-associated steatohepatitis (MASH), VK2809, has also yielded positive results in Phase II trials. This condition, closely related to obesity, affects millions of people in the United States. With only two approved drugs currently available, there is a significant unmet medical need.
Although Viking Therapeutics’ R&D pipeline is attractive, investors must clearly recognize the significant risks involved. If its core projects encounter setbacks, the company’s stock price could face substantial adjustments, and recovery would be exceptionally difficult. In contrast, Eli Lilly, as an industry leader, possesses a mature product portfolio and stable revenue streams, giving it stronger risk resilience.
For investors with a higher risk tolerance, Viking Therapeutics indeed offers considerable potential. If its R&D plans proceed smoothly, the company’s value could achieve significant growth. Therefore, while fully acknowledging the risks, allocating a moderate portion to this stock might be a good choice, but it is essential to control position size and maintain a reasonable balance within the investment portfolio.
